December 9, 2021
Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.
Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.
The Surfers and guest Jörn Schattenberg review NASH-TAG 2022, a unique event and the first meeting on the 2022 NAFLD and NASH calendar.
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbreaking paper “Advancing the Global Health Agenda for NAFLD.”
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbreaking paper “Advancing the Global Health Agenda for NAFLD.” This conversation focuses on the question “What’s Next,” which makes the scale of the challenge clear and compelling.
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbreaking paper “Advancing the Global Health Agenda for NAFLD.”
Lead author Jeffrey Lazarus and co-author Jörn Schattenberg join Stephen Harrison, Louise Campbell and Roger Green to discuss the groundbreaking paper “Advancing the Global Health Agenda for NAFLD.” In this conversation, Jeff discusses how the study was executed, Jörn describes his role and Stephen Harrison comments from a physician’s perspective.
The Surfers convene to discuss “Advancing the Public Health Agenda for NASH,” a paper recently published in Nature Reviews Gastroenterology and Hepatology, with lead author Jeffrey Lazarus and co-author Jörn Schattenberg.
This episode focuses on the importance of NASH cirrhosis clinical trials. The conversation summarizes the status of four ongoing trials and addresses issues of disease naming and the value of incorporating MRE into trial designs.
The Surfers and guest Jörn Schattenberg review NASH-TAG 2022, a unique event and the first meeting on the 2022 NAFLD and NASH calendar.
Dive deep with the surfers! We launched our new private discussion groups on LinkedIn and Facebook so that our listeners get direct access to our surfers about current topics.